Emmanuelle Charpentier. Photo: Hallbauer and Fioretti
Emmanuelle Charpentier has described the possibilities of this technology as "mind blowing". With new possibilities come also the ethical and juridical questions. Are cells that have been changed using this technology, really gene modified, and therefore covered by current regulations? Or can the changes in their genome be compared to natural variation and selection?
The CRISPR-Cas9 technology is indeed revolutionary and may well be awarded a Nobel prize, perhaps already in 2017.
Emmanuelle Charpentier is Director at the Max Planck Institute for Infection Biology, Berlin Germany and Visiting Professor at Umeå University, Sweden, Honorary Professor at Humboldt University, Berlin Germany.
Ragnhild Eskeland is principal investigator at the Department of Biosciences at University of Oslo.
Olav Gjelsvik is professor of philosophy at University of Oslo and director for Center for the Study of mind in nature.
18.00-18.40: Emmanuelle Charpentier: Genome editing by CRISPR-Cas9: Bacterial origin and what is possible, and what may become possible.
18.40-18.50: Comments and questions from the audience
18.50-19.05: Ragnhild Eskeland: CRISPR-Cas9 unravels new knowledge about mammalian chromatin
19.05-19.20: Olav Gjelsvik: Ethics and uncertainty: some aspects.
19.20-19.45: General discussion
The meeting is open and does not require registration.